Benign prostatic hyperplasia progression and its impact on treatment

Area of Science:

• Urology
• Pharmacology
• Men's Health

Background:

• Benign prostatic hyperplasia (BPH) management aims to decrease lifetime risks of acute urinary retention (AUR) and BPH-related surgery.
• 5alpha-reductase inhibitors (5ARIs) offer unique long-term benefits in improving BPH symptoms and flow, while reducing AUR and surgical intervention risks.

Purpose of the Study:

• To review the role of 5ARIs in managing BPH.
• To evaluate the efficacy of 5ARIs alone and in combination with alpha-blockers for BPH treatment.
• To assess the long-term impact of 5ARIs on reducing AUR and the need for surgery.

Main Methods:

• Review of recent studies on 5ARIs in BPH management.
• Analysis of the Medical Therapy of Prostatic Symptoms (MTOPS) study data.
• Evaluation of randomized, placebo-controlled trials assessing dutasteride's efficacy.

Main Results:

• Finasteride, a 5ARI, reduced retention and surgery risk in men with large prostates or high PSA.
• The MTOPS study showed 5ARI-containing arms significantly reduced long-term AUR and invasive therapy risks.
• Dutasteride demonstrated a 57% reduction in AUR risk and a 48% reduction in surgical intervention risk compared to placebo after two years.

Conclusions:

• Short-term combination therapy with 5ARIs and alpha-blockers optimizes symptomatic improvement.
• Initiating 5ARI therapy is crucial for reducing subsequent AUR or BPH-related surgery risks in high-risk patients.
• 5ARIs are essential for long-term risk reduction of AUR and surgical intervention in BPH management.